In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically ...

The conference will be held January 13-16, 2025 in San Francisco, CA. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development ...

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery. A recent ...

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the ...

Finnish researchers, Hanna Heloterä, Anna-Mari Viita, and Juha Laine, reported the results of a study in which they gained a better perspective on registry data and the changing workload in ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.